Raymond James Financial
PTGX icon

Raymond James Financial’s Protagonist Therapeutics PTGX Stock Holding History

Raymond James Financial’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.8M Sell
177,361
-4,142
-2% -$367K 0.01% 1561
2025
Q4 		$15.8M Sell
181,503
-112,793
-38% -$9.23M ﹤0.01% 1606
2025
Q3 		$19.6M Sell
294,296
-17,690
-6% -$1.01M 0.01% 1427
2025
Q2 		$17.2M Buy
311,986
+13,159
+4% +$632K 0.01% 1482
2025
Q1 		$14.5M Sell
298,827
-4,486
-1% -$188K 0.01% 1536
2024
Q4 		$11.7M Buy
+303,313
New +$13.2M ﹤0.01% 1724

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Raymond James Financial's PTGX Position: Q1 2026 in Review

Raymond James Financial reduced its Protagonist Therapeutics (PTGX) stake by 2.3% in Q1 2026, selling an estimated $367K and leaving 177,361 shares worth $17.8M. The position accounts for 0.01% of the portfolio, ranked #1561.

Raymond James Financial first reported a position in PTGX in Q4 2024 and has held it in 6 quarters since. The position peaked at $19.6M in Q3 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Raymond James Financial held 177,361 shares of Protagonist Therapeutics worth $17.8M as of Q1 2026.
  • Raymond James Financial sold 4,142 Protagonist Therapeutics shares in Q1 2026, an estimated $367K.
  • Protagonist Therapeutics made up 0.01% of Raymond James Financial's portfolio in Q1 2026, its #1561 holding.
  • Raymond James Financial first reported a position in Protagonist Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Protagonist Therapeutics position peaked at $19.6M in Q3 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.